“Trial in Progress: A Phase 3 Randomized Study of Low-Dose Intralesional Cemiplimab Versus Primary Surgery for Patients With Early-Stage Cutaneous Squamous Cell Carcinoma (CLEAR CSCC)”, J of Skin, vol. 9, no. 6, p. s689, Nov. 2025, doi: 10.25251/cpgrax68.